基于TGF-β1/Smads信号通路探讨金匮肾气丸联合氯沙坦钾片对老年糖尿病肾病患者肾脏纤维化指标的影响

doi:10.3760/cma.j.cn441417-20241120-12021

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (12): 2033-2038.DOI: 10.3760/cma.j.cn441417-20241120-12021

基于TGF-β1/Smads信号通路探讨金匮肾气丸联合氯沙坦钾片对老年糖尿病肾病患者肾脏纤维化指标的影响

秦刚新¹ 苏衍进¹ 赵莉¹ 王惠铃¹ 杨锦欣²

¹陕西中医药大学附属医院内分泌一科，咸阳 712000；²陕西中医药大学第二附属医院，咸阳 712000

收稿日期:2024-11-20 出版日期:2025-06-15 发布日期:2025-06-15
通讯作者: 杨锦欣，Email：qingangxin@163.com
基金资助:
陕西省重点研发计划（2020SF-336）

To investigate effect of Jinkui Shenqi pills combined with chlorosartan potassium tablets on renal fibrosis indicators in elderly patients with diabetic nephropathy based on TGF-β1/Smads signal pathway

Qin Gangxin¹, Su Yanjin¹, Zhao Li¹, Wang Huiling¹, Yang Jinxin²

¹First Department of Endocrinology, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, China; ²The Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 712000, China

Received:2024-11-20 Online:2025-06-15 Published:2025-06-15
Contact: Yang Jinxin, Email: qingangxin@163.com
Supported by:
Key Plan of Research and Development in Shaanxi Province (2020SF-336)

摘要/Abstract

摘要：

目的　基于转化生长因子-β1（TGF-β1）/Smads信号通路探讨金匮肾气丸联合氯沙坦钾片对老年阴阳两虚型糖尿病肾病患者肾脏纤维化指标的影响。方法　选取2023年1月至2024年1月陕西中医药大学附属医院收治的110例老年阴阳两虚型糖尿病肾病患者进行随机对照试验。采用随机数字表法将其分为对照组和观察组，各55例。观察组男29例，女26例，年龄（68.59±5.48）岁，糖尿病肾病病程（2.14±0.72）年。对照组男32例，女23例，年龄（69.25±5.74）岁，糖尿病肾病病程（2.37±0.68）年。对照组在常规治疗基础上予氯沙坦钾片，观察组在对照组基础上予金匮肾气丸；两组均连续治疗2个月。比较两组治疗前后中医证候积分、血糖水平［空腹血糖（fasting blood glucose，FBG）、餐后2 h血糖（2-hour postprandial blood glucose，2hPBG）］、肾功能指标［尿素氮（blood urea nitrogen，BUN）、肌酐（serum creatinine，SCr）、24 h尿蛋白定量（24-hour urinary protein，24hUpro）］、肾纤维化指标［结缔组织生长因子（connective tissue growth factor，CTGF）、Ⅲ型前胶原（procollagen type Ⅲ，PCⅢ）、层黏蛋白（laminin，LN）、Ⅳ型胶原（collagen type Ⅳ，CⅣ）］水平及TGF-β1、Smad2、Smad3、Smad7蛋白及mRNA的表达。比较两组临床疗效及不良反应发生情况。采用t检验和χ²进行统计分析。结果　治疗前，两组中医证候积分、FBG、2hPBG、BUN、SCr、24hUpro、LN、PCⅢ、CⅣ、CTGF水平及TGF-β1、Smad2、Smad3、Smad7蛋白及mRNA的表达差异均无统计学意义（均P>0.05）。治疗后，两组中医证候积分、FBG、2hPBG、BUN、SCr、24hUpro、LN、PCⅢ、CⅣ、CTGF水平及TGF-β1、Smad2、Smad3蛋白及mRNA的表达均低于治疗前，且观察组均低于对照组（均P<0.05）。治疗后，两组Smad7蛋白及mRNA的表达均高于治疗前，且观察组均高于对照组（均P<0.05）。观察组临床总有效率高于对照组［92.73%（51/55）比72.73%（40/55）；χ²=7.698，P<0.05］。两组不良反应总发生率差异无统计学意义（χ²=0.440，P>0.05）。结论　金匮肾气丸联合氯沙坦钾片治疗老年阴阳两虚型糖尿病肾病患者的效果较好，其或是通过抑制TGF-β1/Smads信号通路的表达，进而改善患者临床症状及肾功能，减轻肾脏纤维化程度。

关键词: 糖尿病肾病, TGF-β1/Smads信号通路, 金匮肾气丸, 氯沙坦钾片, 阴阳两虚型, 肾脏纤维化

Abstract:

Objective　To investigate the effect of Jinkui Shenqi pills combined with chlorosartan potassium tablets on renal fibrosis indicators in elderly patients with diabetic nephropathy of the yin-yang deficiency type based on the transforming growth factor-β1 (TGF-β1) /Smads signal pathway. Methods　A total of 110 elderly patients with diabetic nephropathy of the yin-yang deficiency type treated at Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2023 to January 2024 were selected for the randomized controlled trial, and were divided into a control group and an observation group by the random number table method, with 55 cases in each group. There were 29 males and 26 females in the observation group; they were (68.59±5.48) years old; their disease course was (2.14±0.72) years. There were 32 males and 23 females in the control group; they were (69.25±5.74) years old; their disease course was (2.37±0.68) years. The control group took chlorosartan potassium tablets and conventional treatment; in addition, the observation group took Jinkui Shenqi pills. Both groups were treated continuously for 2 months. The scores of Chinese medicine symptoms, blood glucose levels [fasting blood glucose (FBG) and 2-hour postprandial blood glucose (2hPBG)], levels of renal function indicators [blood urea nitrogen (BUN), serum creatinine (SCr), and 24-hour urinary protein (24hUpro)], levels of renal fibrosis indicators [connective tissue growth factor (CTGF), procollagen type Ⅲ (PCⅢ), laminin (LN), and collagen type Ⅳ (CⅣ)], and protein and mRNA expressions of TGF-β1, Smad2, Smad3, and Smad7 were compared between the two groups before and after the treatment. The clinical efficacies and incidence rates of adverse reactions were compared between the two groups. t and χ² tests were used for the statistical analysis. Results　Before the treatment, there were no statistical differences in the score of traditional Chinese medicine symptoms, levels of FBG, 2hPBG, BUN, SCr, 24hUpro, LN, PCⅢ, CⅣ, and CTGF, and protein and mRNA expressions of TGF-β1, Smad2, Smad3, and Smad7 between the two groups (all P>0.05). After the treatment, the scores of traditional Chinese medicine symptoms, levels of FBG, 2hPBG, BUN, SCr, 24hUpro, LN, PCⅢ, CⅣ, and CTGF, and protein and mRNA expressions of TGF-β1, Smad2, and Smad3 were lower than those before the treatment in both groups, and those in the observation group were lower than those in the control group (all P<0.05). After the treatment, the protein and mRNA expressions of Smad7 were higher than those before the treatment in both groups, and those in the observation group were higher than those in the control group (all P<0.05). The total clinical effective rate of the observation group was higher than that of the control group [92.73% (51/55) vs. 72.73% (40/55); χ²=7.698; P<0.05]. There was no statistical difference in the total incidence rate of adverse reactions between the two groups (χ²=0.440; P>0.05). Conclusion　Jinkui Shenqi pills combined with chlorosartan potassium tablets in the treatment of elderly patients with diabetic nephropathy of the yin-yang deficiency type is effective, which may improve their clinical symptoms and renal function inhibiting the expression of the TGF-β1/Smads signal pathway, and reduce the degree of renal fibrosis.

Key words: Diabetic nephropathy, , TGF-β1/Smads signal pathway, , Jingui Shenqi , pills, , Chlorosartan potassium tablets, , Yin-yang deficiency type, , Renal fibrosis

秦刚新苏衍进赵莉王惠铃杨锦欣. 基于TGF-β1/Smads信号通路探讨金匮肾气丸联合氯沙坦钾片对老年糖尿病肾病患者肾脏纤维化指标的影响 [J]. 国际医药卫生导报, 2025, 31(12): 2033-2038.

Qin Gangxin, Su Yanjin, Zhao Li, Wang Huiling, Yang Jinxin.

To investigate effect of Jinkui Shenqi pills combined with chlorosartan potassium tablets on renal fibrosis indicators in elderly patients with diabetic nephropathy based on TGF-β1/Smads signal pathway [J]. International Medicine and Health Guidance News, 2025, 31(12): 2033-2038.

参考文献

[1]邢文华,梁栋,刘洁,等.线粒体动力学在糖尿病肾病中的作用及调节机制[J].国际医药卫生导报, 2025, 31(2): 183-187. DOI: 10.3760/cmaj.cn441417-20240722- 02002.

[2]Han YC, Tang SQ, Liu YT, et al. AMPK agonist alleviate renal tubulointerstitial fibrosis via activating mitophagy in high fat and streptozotocin induced diabetic mice [J]. Cell Death Dis, 2021, 12(10): 925. DOI: 10.1038/s41419-021-04184-8.

[3]张雪琴,张桂瑛.滋肾泄浊方联合氯沙坦钾片治疗老年早期糖尿病肾病的疗效[J].中国老年学杂志,2024,44(2):351-353. DOI:10.3969/j.issn.1005-9202.2024.02.029.

[4]中国中西医结合学会内分泌专业委员会糖尿病肾脏病专家委员会,中国微循环学会中医与微循环专业委员会.糖尿病肾脏病中西医结合防治专家共识(2023版)[J].中华糖尿病杂志,2023,15(8):690-702. DOI:10.3760/cma.j.cn115791-20230523-00216.

[5]王毅强,越东杰,王俪娟,等.金匮肾气丸对阴阳两虚型糖尿病肾病患者的临床疗效[J].中成药,2023,45(12):4179-4184. DOI:10.3969/j.issn.1001-1528.2023.12.057.

[6]Pang R, Gu D. Triptolide improves renal injury in diabetic nephropathy rats through TGF-β1/Smads signal pathway [J]. Endocr Metab Immune Disord Drug Targets, 2021, 21(10): 1905-1911. DOI: 10.2174/1871530320666201208110209.

[7]Chen Y, Lin X, Zheng Y, et al.Dendrobium mixture ameliorates diabetic nephropathy in db/db mice by regulating the TGF-β1/Smads signaling pathway [J]. Evid Based Complement Alternat Med, 2021: 9931983. DOI: 10.1155/2021/9931983.

[8]中华医学会肾脏病学分会专家组.糖尿病肾脏疾病临床诊疗中国指南[J].中华肾脏病杂志,2021,37(3):255-304. DOI:10.3760/cma.j.cn441217-20201125-00041.

[9]中华中医药学会肾病分会.糖尿病肾病诊断、辨证分型及疗效评定标准 (试行方案)[J].上海中医药杂志,2007,41(7):7-8. DOI:10.3969/j.issn.1007-1334.2007.07.003.

[10]郑筱萸.中药新药临床研究指导原则(试行) [M].北京:中国医药科技出版社, 2002: 119-121.

[11]刘冬梅,林钟鸿.金匮肾气丸对阴阳两虚型糖尿病肾病患者血糖水平及肾功能的改善效果[J].内蒙古中医药,2022,41(7):18-19. DOI:10.16040/j.cnki.cn15-1101.2022. 07.039.

[12]曾培洪,何云,陈梅芬.金匮肾气丸加减治疗糖尿病肾病的临床疗效[J].糖尿病新世界,2024,27(5):171-174. DOI:10.16658/j.cnki.1672-4062.2024.05.171.

[13]马超,冯笑,许丽华.金匮肾气丸加减联合西药治疗Ⅲ～Ⅳ期糖尿病肾病的临床疗效分析[J].世界复合医学,2023,9(6):149-152. DOI: 10.11966/j.issn.2095- 994X. 2023.09.06.41.

[14]侯文雁,宋玮,吴敬,等.金匮肾气丸联合坎地沙坦酯治疗老年糖尿病肾病的疗效及对微炎症状态的影响[J].中国老年学杂志,2023,43(16):3936-3939. DOI: 10.3969/j.issn.1005-9202.2023.16.029.

[15]吴小翠,程亚伟,张永杰,等.加味金匮肾气丸对糖尿病肾病(脾肾阳虚型)患者RBP4、GSK-3β、TGF-β1、NAG及肾功能的影响[J].中国老年学杂志,2022,42(7):1676-1680. DOI: 10.3969/j.issn.1005-9202.2022.07.041.

[16]李丽燕,陈建欧,郑旭旭.单侧输尿管梗阻肾纤维化大鼠模型中肾组织HGF、MBP-7、TGF-β、CTGF的表达变化[J].重庆医学,2020,49(7):1072-1077. DOI:10.3969/j.issn.1671-8348.2020.07.009.

[17]张明昊,俎兆轩,张童,等.金匮肾气丸对肾纤维化模型大鼠的干预作用及机制[J].中国药房,2022,33(15):1848-1853,1859. DOI:10.6039/j.issn.1001-0408.2022.15.11.

[18]Thomas HY, Ford Versypt AN. Pathophysiology of mesangial expansion in diabetic nephropathy: mesangial structure, glomerular biomechanics, and biochemical signaling and regulation [J]. J Biol Eng, 2022, 16(1):19. DOI: 10.1186/s13036-022-00299-4.

[19]Loeffler I, Liebisch M, Allert S, et al. FSP1-specific SMAD2 knockout in renal tubular, endothelial, and interstitial cells reduces fibrosis and epithelial-to-mesenchymal transition in murine STZ-induced diabetic nephropathy [J]. Cell Tissue Res, 2018, 372(1): 115-133. DOI: 10.1007/s00441-017-2754-1.

[20]吴锋,韦丽.桑叶生物碱抑制糖尿病肾病大鼠肾间质纤维化的研究[J].临床肾脏病杂志, 2022, 22(8): 666-673. DOI:10.3969/j.issn.1671-2390.2022.08.008.

[21]Wang W, Zhang J, Wang X, et al. Effects of melatonin on diabetic nephropathy rats via Wnt/β-catenin signaling pathway and TGF-β-Smad signaling pathway [J]. Int J Clin Exp Pathol, 2018, 11(5): 2488-2496.

[22]Chen C, Chen J, Wang Y, et al. Ganoderma lucidum polysaccharide inhibits HSC activation and liver fibrosis via targeting inflammation, apoptosis, cell cycle, and ECM-receptor interaction mediated by TGF-β/Smad signaling [J]. Phytomedicine, 2023, 110: 154626. DOI: 10.1016/j.phymed.2022.154626.

基于TGF-β1/Smads信号通路探讨金匮肾气丸联合氯沙坦钾片对老年糖尿病肾病患者肾脏纤维化指标的影响

To investigate effect of Jinkui Shenqi pills combined with chlorosartan potassium tablets on renal fibrosis indicators in elderly patients with diabetic nephropathy based on TGF-β1/Smads signal pathway

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	魏歆林杨会会刘林波熊朝亮. 尿外泌体miR-155及脂水平与糖尿病肾病严重程度的相关性分析 [J]. 国际医药卫生导报, 2025, 31(6): 949-954.
[2]	邢文华梁栋刘洁李梦洁张晓敏. 线粒体动力学在糖尿病肾病中的作用及调节机制 [J]. 国际医药卫生导报, 2025, 31(2): 183-187.
[3]	杨文娟吕倩倩王杰刘晓宁强薇边芳. 探讨血清Perilipin-2联合尿Netrin-4预测2型糖尿病患者糖尿病肾病的临床价值 [J]. 国际医药卫生导报, 2025, 31(2): 193-197.
[4]	郭志梅王明明. 多学科协作下路径护理对老年糖尿病肾病维持性血液透析肌少症患者的效果 [J]. 国际医药卫生导报, 2025, 31(2): 208-213.
[5]	解晖赵珊庞晖冯萌李娜张艳利. 血管内皮功能与DN患者并发缺血性心脑血管病的关系 [J]. 国际医药卫生导报, 2025, 31(12): 2011-2016.
[6]	马利军刘占军韩继明. miR-150-5p、miR-135b在糖尿病肾病患者中的表达及意义 [J]. 国际医药卫生导报, 2024, 30(9): 1454-1459.
[7]	邹皓珍杨佳席哲帆纪瑞董华. 单细胞RNA测序技术在肾病中的研究进展 [J]. 国际医药卫生导报, 2024, 30(8): 1307-1311.
[8]	刘睿茜杨阳高金祥. 应用托伐普坦治疗糖尿病肾病综合征所致顽固性水肿个案分析 [J]. 国际医药卫生导报, 2024, 30(7): 1172-1176.
[9]	邹皓珍杨佳席哲帆纪瑞董华. 单细胞RNA测序应用于继发性肾病的研究进展 [J]. 国际医药卫生导报, 2024, 30(6): 936-940.
[10]	温俊萍周艳颜彭晓辉. 5E护理模式在糖尿病肾病患者中的应用效果 [J]. 国际医药卫生导报, 2024, 30(5): 793-796.
[11]	陈颖段爽莉李丽. 达格列净联合德谷胰岛素利拉鲁肽注射液治疗血糖控制欠佳糖尿病肾病患者的效果 [J]. 国际医药卫生导报, 2024, 30(23): 4009-4014.
[12]	王荔敏董恒利. 纤维蛋白原和外周血白细胞与糖尿病肾病患者肾功能损伤程度的关系 [J]. 国际医药卫生导报, 2024, 30(13): 2198-2203.
[13]	苏佩合郭晓静. 血清Fetuin-A联合FABP4预测2型糖尿病患者肾病发病风险的价值 [J]. 国际医药卫生导报, 2024, 30(11): 1898-1904.
[14]	陈文清管保章. 糖尿病肾病合并妊娠研究进展 [J]. 国际医药卫生导报, 2024, 30(1): 15-20.
[15]	蔡荣丹刘建帅冯俊霞张云芳刘云启王雅宁. 铁死亡在糖尿病肾病中的研究进展 [J]. 国际医药卫生导报, 2023, 29(9): 1193-1197.